Symbols

ICCM

IceCure Medical·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ICCM

Icecure Medical Ltd.

A medical device company that developing advance treatment for cancerous tumors

Industry

Healthcare Equipment and Supplies

Established Date

Listing Date

08/26/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.icecure-medical.com

Security Type

Common stock

Office address

7 HaEshel St., PO Box 3163, Caesarea, 3079504 Israel

Business

Focus on the research, development and marketing of cryoablation systems and technologies for the treatment of tumors with liquid nitrogen or LN 2.

Introduction

IceCure Medical Ltd., was incorporated in Israel in 2006. The Company is a commercial-stage medical device company focused on the research, development and marketing of cryoablation systems and technologies for the treatment of tumors with liquid nitrogen or LN 2. Their proprietary cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in breast, lung, kidney, bone and other indications. Their industry-leading commercial cryoablation product is the ProSense system.

Earnings Call

Q1/2025

Estimate EPS-0.08

Actual EPS0.06

Estimate Revenue750.00K

Actual Revenue725.00K

IceCure Medical's Q1 2025: Key Contradictions in FDA Studies, Sales Strategies, and Team Expansion

May 28,2025 04:32·
Earnings Decrypt

Q2/2025

Estimate EPS-0.06

Actual EPS-0.06

Estimate Revenue662.50K

Actual Revenue525.00K

IceCure Medical's 2025Q2 Earnings Call: Navigating Contradictions in FDA Approval and Commercialization Strategy

Aug 13,2025 01:15·
Earnings Decrypt

Company Financials

EPS

ICCM has released its 2025 Q3 earnings. EPS was reported at -0.06, versus the expected -0.05, missing expectations. The chart below visualizes how ICCM has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ICCM has released its 2025 Q3 earnings report, with revenue of 850.00K, reflecting a YoY change of 28.40%, and net profit of -3.86M, showing a YoY change of 6.99%. The Sankey diagram below clearly presents ICCM's revenue sources and cost distribution.